Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

602 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial.
Tak PP, Mease PJ, Genovese MC, Kremer J, Haraoui B, Tanaka Y, Bingham CO 3rd, Ashrafzadeh A, Travers H, Safa-Leathers S, Kumar S, Dummer W. Tak PP, et al. Arthritis Rheum. 2012 Feb;64(2):360-70. doi: 10.1002/art.33353. Arthritis Rheum. 2012. PMID: 22389919 Free article. Clinical Trial.
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.
van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, Kivitz AJ, Alvaro J, Nuki G, Furst DE, Herrero-Beaumont G, McInnes IB, Musikic P, Tak PP. van Holten J, et al. Among authors: tak pp. Ann Rheum Dis. 2005 Jan;64(1):64-9. doi: 10.1136/ard.2003.020347. Epub 2004 Jul 8. Ann Rheum Dis. 2005. PMID: 15242865 Free PMC article. Clinical Trial.
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.
Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, Dougados M, Burmester GR, Greenwald M, Kvien TK, Williams S, Hagerty D, Cravets MW, Shaw T. Keystone E, et al. Among authors: tak pp. Ann Rheum Dis. 2009 Feb;68(2):216-21. doi: 10.1136/ard.2007.085787. Epub 2008 Apr 3. Ann Rheum Dis. 2009. PMID: 18388156 Clinical Trial.
Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients.
Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld FC, Tak PP. Kraan MC, et al. Among authors: tak pp. Arthritis Rheum. 2000 Jul;43(7):1488-95. doi: 10.1002/1529-0131(200007)43:7<1488::AID-ANR11>3.0.CO;2-G. Arthritis Rheum. 2000. PMID: 10902750 Free article. Clinical Trial.
Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.
Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, Veale DJ, Breedveld FC, Emery P, Tak PP. Kraan MC, et al. Among authors: tak pp. Arthritis Rheum. 2000 Aug;43(8):1820-30. doi: 10.1002/1529-0131(200008)43:8<1820::AID-ANR18>3.0.CO;2-D. Arthritis Rheum. 2000. PMID: 10943872 Free article. Clinical Trial.
Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.
Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, Wijbrandts CA, Tak PP, Lems WF, Dijkmans BA, van Vugt RM, Wolbink GJ. Korswagen LA, et al. Among authors: tak pp. Arthritis Rheum. 2011 Apr;63(4):877-83. doi: 10.1002/art.30209. Arthritis Rheum. 2011. PMID: 21452312 Free article.
602 results